These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1695 related articles for article (PubMed ID: 30670819)

  • 1. Gut microbial metabolites in obesity, NAFLD and T2DM.
    Canfora EE; Meex RCR; Venema K; Blaak EE
    Nat Rev Endocrinol; 2019 May; 15(5):261-273. PubMed ID: 30670819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbiota, Obesity and NAFLD.
    Lau LHS; Wong SH
    Adv Exp Med Biol; 2018; 1061():111-125. PubMed ID: 29956210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota and its metabolic potential.
    Czajkowska A; Kaźmierczak-Siedlecka K; Jamioł-Milc D; Gutowska I; Skonieczna-Żydecka K
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12971-12977. PubMed ID: 33378048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics.
    He X; Ji G; Jia W; Li H
    Int J Mol Sci; 2016 Mar; 17(3):300. PubMed ID: 26999104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.
    Vallianou N; Stratigou T; Christodoulatos GS; Dalamaga M
    Curr Obes Rep; 2019 Sep; 8(3):317-332. PubMed ID: 31175629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faecal microbial metabolites of proteolytic and saccharolytic fermentation in relation to degree of insulin resistance in adult individuals.
    Hernández MAG; Canfora EE; Blaak EE
    Benef Microbes; 2021 Jun; 12(3):259-266. PubMed ID: 33880973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging role of intestinal microbiota and microbial metabolites in metabolic control.
    Herrema H; IJzerman RG; Nieuwdorp M
    Diabetologia; 2017 Apr; 60(4):613-617. PubMed ID: 28013341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.
    Aron-Wisnewsky J; Vigliotti C; Witjes J; Le P; Holleboom AG; Verheij J; Nieuwdorp M; Clément K
    Nat Rev Gastroenterol Hepatol; 2020 May; 17(5):279-297. PubMed ID: 32152478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the gut microbiome and its metabolites in metabolic diseases.
    Wu J; Wang K; Wang X; Pang Y; Jiang C
    Protein Cell; 2021 May; 12(5):360-373. PubMed ID: 33346905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut Microbes in Polycystic Ovary Syndrome and Associated Comorbidities; Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease (NAFLD), Cardiovascular Disease (CVD), and the Potential of Microbial Therapeutics.
    Singh V; Mahra K; Jung D; Shin JH
    Probiotics Antimicrob Proteins; 2024 Oct; 16(5):1744-1761. PubMed ID: 38647957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation analysis of gut microbiota and biochemical indexes in patients with non-alcoholic fatty liver disease].
    Ren SM; Mei L; Huang H; Cao SF; Zhao RH; Zheng PY
    Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):369-375. PubMed ID: 31177662
    [No Abstract]   [Full Text] [Related]  

  • 13. Integrated omics analysis unraveled the microbiome-mediated effects of Yijin-Tang on hepatosteatosis and insulin resistance in obese mouse.
    Lee JE; Lee SM; Jung J
    Phytomedicine; 2020 Dec; 79():153354. PubMed ID: 32992082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.
    Jayakumar S; Loomba R
    Aliment Pharmacol Ther; 2019 Jul; 50(2):144-158. PubMed ID: 31149745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Sesquiterpene Glycoside from Loquat Leaf Alleviates Type 2 Diabetes Mellitus Combined with Nonalcoholic Fatty Liver Disease by Improving Insulin Resistance, Oxidative Stress, Inflammation, and Gut Microbiota Composition.
    Chen J; Ding X; Wu R; Tong B; Zhao L; Lv H; Meng X; Liu Y; Ren B; Li J; Jian T; Li W
    J Agric Food Chem; 2021 Dec; 69(47):14176-14191. PubMed ID: 34783554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification.
    Panasevich MR; Peppler WT; Oerther DB; Wright DC; Rector RS
    Physiol Genomics; 2017 Aug; 49(8):385-399. PubMed ID: 28600319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.
    Ma J; Zhou Q; Li H
    Nutrients; 2017 Oct; 9(10):. PubMed ID: 29035308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interplay between host cellular and gut microbial metabolism in NAFLD development and prevention.
    Yu SY; Xu L
    J Appl Microbiol; 2021 Aug; 131(2):564-582. PubMed ID: 33411984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Metabolic Role of the Microbiome: Implications for NAFLD and the Metabolic Syndrome.
    Quigley EM; Abu-Shanab A; Murphy EF; Stanton C; Monsour HP
    Semin Liver Dis; 2016 Sep; 36(4):312-316. PubMed ID: 27997970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The intestinal microbiome and metabolic diseases : From obesity to diabetes and nonalcoholic steatohepatitis].
    Bischoff SC
    Internist (Berl); 2017 May; 58(5):441-448. PubMed ID: 28432400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 85.